CAI SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 4, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 8, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 3, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Nov 4, 2026

8-K

Caris Life Sciences Announces Investor Presentation at Morgan Stanley 24th Annual Global Healthcare Conference

Sep 14, 2026

8-K

Caris Life Sciences Reports Q2 2026 Financial Results and Increases Full Year Revenue Guidance

Aug 5, 2026

8-K

Caris Life Sciences, Inc. Announces Results of 2026 Annual Meeting of Shareholders

Jun 5, 2026

8-K

Caris Life Sciences Reports First Quarter 2026 Financial Results with 79% Revenue Growth

May 7, 2026

8-K

Caris Life Sciences, Inc. Enters Into New $1.2 Billion Senior Secured Credit Agreement

Apr 2, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B4

OFFERING (Initial Public Offering) - BofA Securities, J.P. Morgan, Goldman Sachs & Co. LLC, Citigroup, TD Cowen, Evercore ISI, Guggenheim Securities, BTIG, Wolfe | Nomura Alliance | Shares amount: 23,529,412 | Share price: $21 | Offering amount: $494,117,652

Jun 18, 2025

Registrations

TYPE

HEADLINE

FILED AT

8-A12B

Form 8-A12B - Registration of securities [Section 12(b)]

Jun 16, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jun 18, 2025

S-1/A

Jun 16, 2025

8-A12B

Form 8-A12B - Registration of securities [Section 12(b)]

Jun 13, 2025

S-1/A

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Jun 9, 2025

S-1

Form S-1 - General form for registration of securities under the Securities Act of 1933

May 23, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 23, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 23, 2026

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

FMR LLC (Filed by)

Nov 5, 2026

Denton John Russel (Reporting)

Sep 23, 2026

144

Form 144 - Report of proposed sale of securities

Sep 22, 2026

Brille Brian J (Reporting)

Sep 17, 2026

144

Form 144 - Report of proposed sale of securities

Sep 17, 2026

Spetzler David Baxley (Reporting)

Sep 4, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Jun 18, 2025

CORRESP

Form CORRESP - Correspondence

Jun 13, 2025

CORRESP

Form CORRESP - Correspondence

Jun 13, 2025

LETTER

Form UPLOAD - SEC-generated letter

Apr 16, 2025

LETTER

Form UPLOAD - SEC-generated letter

Jan 10, 2025

LETTER

Form UPLOAD - SEC-generated letter

Sep 26, 2024

Caris Life Sciences, Inc. CAI · SEC Filings